Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
4.060
-0.190 (-4.47%)
Sep 25, 2025, 3:37 PM EDT - Market open
Voyager Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Voyager Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $16.71, which forecasts a 311.58% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $30.
Price Target: $16.71 (+311.58%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Voyager Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +638.92% | Sep 15, 2025 |
| Wedbush | Wedbush | Buy Maintains $9 → $8 | Buy | Maintains | $9 → $8 | +97.04% | Aug 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +638.92% | Apr 8, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 → $12 | Strong Buy | Maintains | $14 → $12 | +195.57% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +638.92% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
30.68M
from 80.00M
Decreased by -61.65%
Revenue Next Year
63.53M
from 30.68M
Increased by 107.07%
EPS This Year
-2.16
from -1.13
EPS Next Year
-1.52
from -2.16
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.4M | 153.3M | |||
| Avg | 30.7M | 63.5M | |||
| Low | 21.2M | 7.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -40.8% | 399.5% | |||
| Avg | -61.6% | 107.1% | |||
| Low | -73.5% | -74.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.86 | -0.50 | |||
| Avg | -2.16 | -1.52 | |||
| Low | -2.25 | -2.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.